Management of tuberculosis in the United States

New England Journal of Medicine

Volumn 345, Issue 3, 2001, Pages 189-200

  Small, Peter M ^a   Fujiwara, Paula I ^b,c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK CITY DEPARTMENT OF HEALTH AND MENTAL HYGIENE   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; CAPREOMYCIN; CIPROFLOXACIN; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; OFLOXACIN; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; RIFAPENTINE; STREPTOMYCIN;

CLINICAL FEATURE; DISEASE TRANSMISSION; DRUG INDUCED DISEASE; GASTROINTESTINAL SYMPTOM; HUMAN; NEPHROTOXICITY; OTOTOXICITY; PREVALENCE; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME; TUBERCULIN TEST; TUBERCULOSIS;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTITUBERCULAR AGENTS; HUMANS; PRACTICE GUIDELINES; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; UNITED STATES;

EID: 0035913260     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200107193450307     Document Type: Review

References (85)

1. Epidemiology of tuberculosis in the United States, 1985 through 1992
2. The U-shaped curve of concern
3. A strategic plan for the elimination of tuberculosis in the United States
4. Tuberculosis in New York City - Turning the tide
5. The epidemiology of tuberculosis among foreign-born persons in the United States, 1986 to 1993
6. Long-term risk of tuberculosis among foreign-born persons in the United States
7. Cluster of tuberculosis cases among exotic dancers and their close contacts - Kansas, 1994-2000
8. Consensus statement: Global burden of tuberculosis: Estimated incidence, prevalence, and mortality by country: WHO Global Surveillance and Monitoring Project
9. The proportion of tuberculosis cases in Tanzania attributable to human immunodeficiency virus
10. Standard short-course chemotherapy for drug-resistant tuberculosis: Treatment outcomes in 6 countries
11. Research issues involving HIV-associated tuberculosis in resource-poor countries
12. The pathogenesis of tuberculosis
13. Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection
14. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment
15. Tuberculosis control and molecular epidemiology in a South African gold-mining community
16. Diagnostic standards and classification of tuberculosis in adults and children
17. Impact of human immunodeficiency virus infection on the epidemiology, clinical features, management, and control of tuberculosis
18. TB-AIDS versus non-AIDS TB cases, United States, 1993-1997
19. Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection
20. Tuberculosis in relation to human immunodeficiency virus and acquired immunodeficiency syndrome
21. Rifapentine: Its role in the treatment of tuberculosis
22. Linezolid
23. Once-daily and twice-daily dosing of p-aminosalicylic acid granules
24. Linezolid
25. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications
26. Tuberculosis chemotherapy including directly observed therapy
27. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: Principles of therapy and revised recommendations
28. Treatment of tuberculosis and tuberculosis infection in adults and children
29. Resurgent tuberculosis in New York City: Human immunodeficiency virus, homelessness, and the decline of tuberculosis control programs
30. Directly observed therapy in New York City: History, implementation, results, challenges
31. Control of tuberculosis in the United States
32. Directly observed therapy for treatment completion of pulmonary tuberculosis: Consensus statement of the Public Health Tuberculosis Guidelines Panel
33. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once weekly rifapentine and isoniazid
34. TBTC study 22 (rifapentine trial): Preliminary results in HIV-negative patients
35. The course of fever during treatment of pulmonary tuberculosis
36. Impact of HIV infection on tuberculosis
37. Controlled trial of 6-month and 9-month regimens of daily and intermittent streptomycin plus isoniazid plus pyrazinamide for pulmonary tuberculosis in Hong Kong: The results up to 30 months
38. Treatment of multidrug-resistant tuberculosis
39. The treatment of tuberculosis
40. The treatment of multidrug-resistant tuberculosis in Turkey
41. Targeted tuberculin testing and treatment of latent tuberculosis infection
42. Controlled chemoprophylaxis trials in tuberculosis: A general review
43. Conversion and reversion of tuberculin reactions in nursing home residents
44. Screening for tuberculosis and tuberculosis infection in high-risk populations: Recommendations of the Advisory Committee for Elimination of Tuberculosis
45. Tuberculin skin testing
46. The role of BCG vaccine in the prevention and control of tuberculosis in the United States: A joint statement by the Advisory Council for the Elimination of Tuberculosis and the Advisory Committee on Immunization Practices
47. Reliability of anergy skin testing in persons with HIV infection
48. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis
49. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus
50. Anergy skin testing and preventive therapy for HIV-infected persons: Revised recommendations
51. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: Five years of follow-up in the IUAT trial
52. Preventive therapy with isoniazid: Cost-effectiveness of different durations of therapy
53. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?
54. Isoniazid prophylaxis for tuberculosis in HIV infection: A meta-analysis of randomized controlled trials
55. Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection
56. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: An international randomized trial
57. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia
58. Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection - New York and Georgia, 2000
59. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong
60. Management of persons exposed to multidrug-resistant tuberculosis
61. Genetic advances for studying Mycobacterium tuberculosis pathogenicity
62. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase
63. Identification of a virulence gene cluster of Mycobacterium tuberculosis by signature-tagged transposon mutagenesis
64. Exploring drug-induced alterations in gene expression in Mycobacterium tuberculosis by microarray hybridization
65. Genetic susceptibility to tuberculosis in Africans: A genome-wide scan
66. A proposed national strategy for tuberculosis vaccine development
67. Correlates of protective immunity to Mycobacterium tuberculosis in humans
68. A molecular epidemiologic analysis of tuberculosis trends in San Francisco 1991-1997
69. Evaluation of the tuberculin gamma interferon assay: Potential to replace the Mantoux skin test
70. Comparative genomics of BCG vaccines by whole-genome DNA microarray
71. Comparative proteome analysis of Mycobacterium tuberculosis and Mycobacrerium bovis BCG strains: Towards functional genomics of microbial pathogens
72. Specific immune-based diagnostics of tuberculosis
73. Molecular determinants of drug resistance in tuberculosis
74. Rifapentine: Its role in the treatment of tuberculosis
75. Cytokine therapy of mycobacterial infections
76. More rigour needed in trials of new diagnostic agents for tuberculosis
77. Essential components of a tuberculosis prevention and control program: Recommendations of the Advisory Council for the Elimination of Tuberculosis